Xilio Therapeutics Q1 EPS $(0.18) Misses $0.10 Estimate, Sales $2.93M Miss $4.40M Estimate

Benzinga · 05/08 11:38
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.10 by 280 percent. This is a 69.49 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $2.93 million which missed the analyst consensus estimate of $4.40 million by 33.41 percent.